Clinical trial · Observational
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
A National Multicenter, Noninterventional Clinical Study Evaluating the Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
NCT05381753CI-TRIAL-00102983completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Avapritinib | Drug | Avapritinib | ALIAS |
| Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al ) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Ava-mGSIT-P18
- description
- Unresectable or metastatic PDGFRA exon 18 GIST
- interventionNames
- Drug: Avapritinib
- label
- Ava-Perioperative
- description
- Perioperative PDGFRA exon 18 GIST
- interventionNames
- Drug: Avapritinib
- label
- Ava-mGIST-other
- description
- Unresectable or metastatic GIST without KIT exon 13，14，or PDGFRA exon 18 mutation
- interventionNames
- Drug: Avapritinib
- label
- TKI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cohort 1 and 4: Participants must have a confirmed diagnosis of unresectable GIST with mutations in the PDGFRα gene exon 18. * Cohort 2: Participants must have a confirmed diagnosis of GIST with mutations in the PDGFRα gene exon 18 and was/will be administrated avapritinib in an neoadjuvant and/or adjuvant setting. * Cohort 3: Participants must have a confirmed diagnosis of unresectable GIST without mutations in the PDGFRα gene exon 18, KIT gene exon 13, and KIT gene exon 14. Exclusion Criteria: * Participants who have participated and may participate in any other interventional clinical trail in the future. * Participants with any comorbidities not suitable for avapritinib (other TKIs, Cohort 4) treatment assessed by researchers.
References
Publications (0)
Data not yet available
No reference posted for this study.